EP Patent

EP3388428B1 — Five-membered heterocyclic amides wnt pathway inhibitor

Assigned to Evopoint Biosciences Co Ltd · Expires 2021-08-04 · 5y expired

What this patent protects

Patent listed against Nubeqa.

Drugs covered by this patent

Patent Metadata

Patent number
EP3388428B1
Jurisdiction
EP
Classification
—
Expires
2021-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Evopoint Biosciences Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.